Cargando…
Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis
Prevalence and risk factors for hepatic steatosis (HS) in the human immunodeficiency virus (HIV)-positive population of western countries are controversially discussed and potentially confounded by coinfection with viral hepatitis. Significant HS (more than 10% of hepatocytes) can be accurately asse...
Autores principales: | Mohr, Raphael, Boesecke, Christoph, Dold, Leona, Schierwagen, Robert, Schwarze-Zander, Carolynne, Wasmuth, Jan-Christian, Weisensee, Insa, Rockstroh, Jürgen Kurt, Trebicka, Jonel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944472/ https://www.ncbi.nlm.nih.gov/pubmed/29702998 http://dx.doi.org/10.1097/MD.0000000000010462 |
Ejemplares similares
-
Liver Fibrosis in HIV Patients Receiving a Modern cART: Which Factors Play a Role?
por: Mohr, Raphael, et al.
Publicado: (2015) -
Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)
por: Bischoff, Jenny, et al.
Publicado: (2021) -
Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART
por: Dold, Leona, et al.
Publicado: (2019) -
Genetic polymorphisms associated with fatty liver disease and fibrosis in HIV positive patients receiving combined antiretroviral therapy (cART)
por: Dold, Leona, et al.
Publicado: (2017) -
Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients
por: Anadol, Evrim, et al.
Publicado: (2018)